Quick Answer
Oncotelic Therapeutics, Inc. reported Operating Income of -$3.58 million for fiscal year 2024.
Oncotelic Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$3.58M | +46.2% |
| 2023 | -$6.65M | +31.6% |
| 2022 | -$9.72M | -6.5% |
| 2021 | -$9.13M | -20.3% |
| 2020 | -$7.58M | -75.9% |
| 2019 | -$4.31M | -504.8% |
| 2018 | -$712.7K | +94.9% |
| 2017 | -$13.84M | -0.6% |
| 2016 | -$13.76M | -0.6% |
| 2015 | -$13.68M | -8.2% |
| 2014 | -$12.65M | -52.8% |
| 2013 | -$8.28M | -2.6% |
| 2012 | -$8.07M | +32.1% |
| 2011 | -$11.89M | +35.8% |
| 2010 | -$18.51M | +40.6% |
| 2009 | -$31.16M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$491.0K | +85.0% | -644.2% |
| June 30, 2025 | -$66.0K | +31.7% | +34.7% |
| March 31, 2025 | -$101.1K | +39.5% | +96.9% |
| September 30, 2024 | -$3.28M | -22760.3% | -3296.9% |
| June 30, 2024 | -$96.6K | +98.5% | +42.2% |
| March 31, 2024 | -$167.2K | +36.7% | -1255.0% |
| September 30, 2023 | $14.5K | +102.4% | +100.2% |
| June 30, 2023 | -$6.32M | -2366.5% | -2293.6% |
- Oncotelic Therapeutics, Inc. showed an increase of +46.2% in Operating Income compared to the prior fiscal year.
- Over the 2009–2024 period, Oncotelic Therapeutics, Inc.’s operating income has grown by 88.5% (from -$31.16 million to -$3.58 million).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: